Inari Medical, Inc. (NARI) witnessed a remarkable surge in its stock price during the pre-market trading session on Tuesday, January 7th, soaring over 21.88%. This significant upward movement was fueled by the announcement that the company has entered into a definitive agreement to be acquired by Stryker Corporation (SYK), a global leader in medical technologies, for $80 per share in cash.
The acquisition, valued at approximately $4.9 billion, represents a strategic move by Stryker to expand its portfolio and establish a leading position in the high-growth segment of peripheral vascular diseases, particularly venous thromboembolism (VTE). Inari Medical's innovative product portfolio, including mechanical thrombectomy solutions for conditions such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing neurovascular business.
According to Kevin Lobo, Chair and Chief Executive Officer of Stryker, "The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases. These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker's impact in endovascular procedures."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.